CSLLY - Haemonetics down 5% as FDA approves plasma collection system to be used by rival

Shares of Haemonetics (HAE -5.5%) are down in late afternoon trading after the FDA approved Terumo Blood and Cell Technologies' Rika Plasma Donation System. Rika will be used by CSL Plasma, the plasma collection business of CSL Limited (OTCPK:CSLLY +1.8%), a rival of Haemonetics (HAE -5.5%). Initially, Rika will be rolled out at CSL Plasma centers in the spring in the Denver area. The machine can collect plasma in 35 minutes or less. Check out Haemonetics' (HAE -5.5%) fiscal 2022 Q3 results.

For further details see:

Haemonetics down 5% as FDA approves plasma collection system to be used by rival